Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating restated by equities research analysts at J P Morgan Chase & Co in a note issued to investors on Monday. They currently have a $76.00 price objective on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective points to a potential upside of 12.96% from the stock’s previous close.
A number of other equities analysts have also recently issued reports on AGIO. BidaskClub cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Needham & Company LLC lifted their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. Finally, Leerink Swann upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $75.20.
Agios Pharmaceuticals (NASDAQ AGIO) traded up 0.74% on Monday, hitting $66.92. 394,584 shares of the company traded hands. The stock’s 50-day moving average is $60.25 and its 200 day moving average is $54.45. The stock’s market cap is $3.24 billion. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business’s revenue was up 62.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.47) EPS. Equities research analysts expect that Agios Pharmaceuticals will post ($7.07) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/09/18/agios-pharmaceuticals-agio-overweight-rating-reaffirmed-at-j-p-morgan-chase-co.html.
In related news, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $65.47, for a total value of $65,470.00. Following the completion of the sale, the director now directly owns 86,394 shares in the company, valued at $5,656,215.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $65.00, for a total transaction of $975,000.00. Following the completion of the sale, the insider now owns 6,264 shares of the company’s stock, valued at $407,160. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,230 shares of company stock valued at $6,245,972. 10.55% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its stake in Agios Pharmaceuticals by 11.7% during the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the period. Blue Sky Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the first quarter worth approximately $129,000. Russell Investments Group Ltd. grew its stake in Agios Pharmaceuticals by 163.9% during the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the period. QS Investors LLC purchased a new stake in Agios Pharmaceuticals during the second quarter worth approximately $144,000. Finally, Cubist Systematic Strategies LLC grew its stake in Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 3,123 shares during the period. Hedge funds and other institutional investors own 94.40% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.